Clinical Trials

56 enrolled

Glioblastoma

NCT04659811 2026-04-15

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

35 enrolled

Meningioma

NCT02359565 2026-04-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Phase 1/2 Active not recruiting

71 enrolled

CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT03277638 2026-04-09

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

32 enrolled

Brain Neoplasms, Glioblastoma

NCT01822652 2026-04-06

GRAIN

11 enrolled

Neuroblastoma, Recurrence

NCT06514898 2026-04-03

MATCHPOINT

12 enrolled

Medulloblastoma

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

52 enrolled 19 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04074096 2026-03-25

BEPCOME-MB

10 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02852655 2026-03-20

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

60 enrolled 19 charts

Brain Neoplasms

NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

60 enrolled

Phase NA Active not recruiting

Astrocytoma, Oligodendroglioma

NCT02658279 2026-03-03

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

27 enrolled

Glioma

NCT03405792 2026-02-06

2-THE-TOP

40 enrolled 11 charts

Glioblastoma

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

CNSEndocrineGenitourinary

157 enrolled 26 charts

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03279692 2026-01-29

Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

26 enrolled 14 charts

Meningioma

NCT04483778 2025-11-20

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

68 enrolled

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04201873 2025-08-22

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

40 enrolled

Glioblastoma

NCT02337686 2025-08-15

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

18 enrolled 12 charts

CNSSarcoma

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1/2 Active not recruiting

1 enrolled

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT04121455 2025-06-25

GLORIA

117 enrolled

Phase 1/2 Active not recruiting

Brain Neoplasms, Glioblastoma

NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

179 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02886585 2024-03-12

Pembrolizumab In Central Nervous System Metastases

101 enrolled